GlassScriptPhysician profile
David Howard Oelsner
NPI 1396760765
$8,367.37
in general payments reported to CMS, 2019-2025
36 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $792 · 2021: $1,485 · 2022: $1,622 · 2023: $978 · 2024: $1,359 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,140.16 | 2019-2025 | |
| Janssen Biotech, INC. | $937.21 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $539.06 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $437.90 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $390.07 | 2020-2023 | |
| Qol Medical, LLC | $324.31 | 2019-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $317.01 | 2019-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $306.67 | 2024-2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.35 | 2019-2024 | Trulance, Xifaxan |
| Regeneron Healthcare Solutions, INC. | $279.22 | 2022-2025 | Dupixent |
| Pfizer INC. | $212.00 | 2019-2025 | |
| Celgene Corporation | $164.88 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $144.67 | 2020-2022 | |
| Genzyme Corporation | $120.68 | 2024-2025 | |
| Madrigal Pharmaceuticals | $101.23 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $80.39 | 2022-2025 | Ibsrela |
| Dynavax Technologies Corporation | $80.01 | 2020-2022 | |
| Braintree Laboratories, INC. | $54.50 | 2020-2022 | |
| Allergan, INC. | $51.41 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $41.70 | 2021-2022 | |
| Orphalan INC | $39.11 | 2025 | Cuvrior |
| Daiichi Sankyo INC. | $34.37 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $34.09 | 2025 | Iqirvo |
| Lucid Diagnostics INC. | $27.52 | 2022 | |
| Boston Scientific Corporation | $23.41 | 2022 | |
| Innovation Technologies INC | $21.38 | 2025 | Irrisept |
| Welch Allyn | $19.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.91 | 2025 | Voquezna |
| Digestive Care, INC. | $17.88 | 2025 | Pertzye |
| Ucb, INC. | $17.63 | 2019 | |
| Shield Therapeutics INC | $16.68 | 2024 | |
| Mylan Institutional INC. | $16.00 | 2023 | Hulio |
| Sandoz INC. | $15.38 | 2024 | Hyrimoz |
| Csl Behring | $15.11 | 2025 | Kcentra |
| Cook Medical LLC | $13.23 | 2022 | |
| Echosens North America, INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oelsner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.